Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_assertion type Assertion NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_head.
- NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_assertion description "[T-cell therapy is one such area where recent trials using T cells genetically modified to express an antibody-based chimeric antigen receptor (CAR) targeted against the CD19 antigen have demonstrated impressive responses when adoptively transferred to patients with advanced chronic lymphocytic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_provenance.
- NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_assertion evidence source_evidence_literature NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_provenance.
- NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_assertion SIO_000772 24329792 NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_provenance.
- NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_assertion wasDerivedFrom befree-20150227 NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_provenance.
- NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_assertion wasGeneratedBy ECO_0000203 NP338536.RA9f-8_on3NQkNyFlZYMZ8pUddqxcHDkAJl8umI_K3Mv4130_provenance.